Edarbi, a high-efficacy angiotensin II receptor blocker, is specifically formulated to manage and lower high blood pressure, aiding in the prevention of cardiovascular risks.
Each bottle contains 30 tablets of Azilsartan Medoxomil at a potency of 80 mg, designed for precise dosage and effective hypertension control.
Produced by Arbor Pharmaceuticals, Edarbi is recognized for its reliability and effectiveness in hypertension management.
Edarbi tablets are an essential part of a comprehensive treatment plan for hypertension, working to improve heart health and reduce the risk of stroke and heart attack.